LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of Liver Regeneration Technology
LyGenesis, a Juvenescence partner, focused on organ regeneration, announced that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, and the Longevity Vision Fund.
October 21, 2019Read More
Insilico Medicine, a next generation AI technology and Juvenescence partner, completes $37 million Series B funding that will be used to commercialize the validated generative chemistry and target identification technology.
September 10, 2019Read More
Insilico Medicine has developed GENTRL, a new artificial intelligence system for drug discovery that dramatically accelerates the process from years to days.
September 2, 2019Read More
AgeX Therapeutics publishes Theoretical Basis of Human Cell-Age Reversal in the Journal of Regenerative Medicine
AgeX Therapeutics, a Juvenescence biotechnology company focused on therapeutics for human aging and regeneration, announced today, the theoretical foundation of the Company’s induced Tissue Regeneration (iTRTM) technology.
August 28, 2019Read More
Juvenescence announces that Colin Watts has joined its Management Team as CEO of Juvenescence Life. Driving Human longevity and quality of life.
July 11, 2019Read More
Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.
May 28, 2019Read More
Juvenescence announces that David Ellam has joined its Executive Management Team as Chief Financial Officer.
April 24, 2019Read More
Juvenescence and the Buck Institute for Research on Aging announce a new collaboration with the formation of BHB Therapeutics a joint venture.
February 4, 2019Read More
Juvenescence is pleased to announce the close of the first tranche of its Series B financing, in the amount of $46 million.
January 16, 2019Read More
.Juvenescence, The Buck Institute for Research on Aging, and Insilico Medicine announced today that they have formed Napa Therapeutics, to develop drugs against a novel aging-related target.
August 14, 2018Read More
Juvenescence Closes Seed Round of USD $12.3 Million with Participation from Seasoned Biotech Investors
Juvenescence announced that it has closed its seed funding round, raising USD $12.3 million. The Seed Round was included undisclosed sums from a range of seasoned international angel investors and institutions.
January 8, 2018Read More